



Drug therapy for atrial fi brillation: 
quo vadis?
INTRODUCTION
This year is the centenary of the fi rst ECG recording of atrial fi brillation 
(AF) by Hering,(1) but drug therapy for the condition was reported long 
before that in 1835 by Bouillaud.(2) Current drug therapy for AF includes 
drugs for ventricular rate control, anti-arrhythmic drugs for rhythm 
control, and anti-coagulants. The 3 essential problems of this arrhythmia 
are symptoms, thrombo-embolism, and tachycardia-induced cardio-
myopathy. The prevention of tachycardia-induced cardiomyopathy 
requires rate control; the prevention of thrombo-embolism requires 
anti-coagulation; and the suppression of symptoms requires rate control 
in all patients and rhythm control in some. Those are patients who have 
symptoms despite rate control or in whom rhythm control is suspected 
to be a better strategy. Rhythm control is suspected to be a better 
strategy in younger patients, when symptoms are severe, in the presence 
of diastolic dysfunction in hypertension or hypertrophic cardiomyopathy, 
and in mitral stenosis.
RATE CONTROL
Current options for rate control include the well-known drugs digoxin, 
rate-slowing calcium channel blockers, viz. verapamil and diltiazem, 
beta-blockers, and amiodarone, and the “ablate and pace” procedure. 
Digoxin, although historically the very fi rst drug used in this condition, 
is known to be rather ineffective, especially when exercise heart rates 
are evaluated, and there is also concern about increased mortality with 
digoxin in females with heart failure (Digoxin Investigation Group 
Trial)(3) especially if the serum level is > 1.2ng/ml,(4) and in both genders 
in the SPORTIF III and V trials in patients with AF.(5) Amiodarone, 
although effi cacious in ventricular rate control, is seldom used for this 
indication alone because of serious non-cardiac toxicity. 
What are future options for rate control? Dronederone is an 
amiodarone congener which is non-iodinated and consequently has 
fewer side-effects, especially thyroid and pulmonary, and consequently 
may well have a place in the future rate control armamentarium. It has 
been shown to lower the ventricular rate by 12bpm at rest and 24bpm 
on exercise in the ERATO trial.(6) A number of adenosine agonists 
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 Atrial fi brillation has always been the 
most common sustained cardiac arrhythmia, and its 
incidence is increasing worldwide. Despite evolving ablation 
techniques, the vastness of the number of cases entrenches 
drug therapy as the mainstay of treatment for the majority 
of cases both now and in the foreseeable future.
Drug therapy for atrial fi brillation includes drugs for ven-
tricular rate control, anti-coagulation, and cardioversion/
maintenance of sinus rhythm (rhythm control). This review 
summarizes the available data on new drugs in each of 
these 3 areas.  
In the area of rhythm control, it is clear that primary 
prevention of atrial fi brillation is achieved by a number of 
drugs in common clinical usage in hypertension, heart 
failure, and vascular disease, viz. blockers of the renin-
angiotensin system and statins. Primary prevention is also 
promising with novel therapies such as anti-infl ammatory 
therapy, pirfenidone, and Ω-3 poly-unsaturated fatty acids. 
Secondary prevention with anti-arrhythmic drugs producing 
multiple channel blockade is proven to be effi cacious, and 
atrial-selective anti-arrhythmic drugs are an attractive 
development and will avoid ventricular pro-arrhythmia.
A number of new drugs with novel mechanisms of 
action have mostly not yet undergone clinical trials, but 
are discussed here, and include gap junction modula-
tors, stretch-activated channel blockers, sodium-calcium 
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specifi c for the A1 receptor are in development and include intravenous 
(tecadenoson) and oral (seladenoson) forms. Direct injection of the AV 
node is feasible because of its sub-endocardial location and  animal 
experiments have shown that cell therapy by injection of fi broblasts in 
this way is possible and that this retards AV conduction. A novel gene 
therapy was reported whereby an adenovirus carrying a transgene, 
namely the alpha subunit of the inhibitory G protein, was injected down 
the AV nodal artery, and resulted in suppression of calcium channel 
activity, and signifi cant slowing of the ventricular response even after 
adrenaline infusion in a porcine model.(7)  
ANTI-COAGULATION
Current options for anti-coagulation in AF consist only of warfarin and 
aspirin. The latest ACC / AHA / ESC guidelines for AF management 
(2006)(8) stratify the risk for thrombo-embolism according to certain 
“major”, “moderate” and “minor” risk factors (Table I). Warfarin is 
recommended if any one major risk factor is present, or if two moderate 
risk factors are present, or if one moderate and a number of minor risk 
factors are present. Low-dose aspirin is recommended for the rest.
New options for anti-coagulation are listed in Table II. Clopidogrel as 
an alternative to aspirin is the subject of an ongoing trial namely 
ACTIVE A. Clopidogrel plus aspirin as an alternative to warfarin has 
proved to be inferior in the ACTIVE W trial.(9) Recently idraparinux in 
comparison to warfarin proved to be more effective at prevention of 
thrombo-embolism, but caused signifi cantly more bleeding (AMADEUS 
trial).(10) A number of direct factor Xa inhibitors are in clinical trials at 
present including apixaban (ARISTOTLE and AVERROES), betrixaban 
(EXPERT) and rivaroxaban (ROCKET-AF). Although the fi rst direct 
thrombin inhibitor ximelagatran has been withdrawn from further 
investigation because of liver toxicity, dabigatran is the subject of the 
ongoing RELY trial which should be reported in the next 2 years. All of 
these trials use warfarin as the comparator.(11)  
RHYTHM CONTROL
Apart from radio-frequency ablation options for rhythm control 
(pulmonary veins, accessory pathway, and cavo-tricuspid isthmus for 
fl utter) in selected patients, the vast majority of patients with AF in 
whom the rhythm control strategy is being pursued, will require drug 
therapy.  Currently in South Africa there are 4 drugs available for this 
purpose, viz. the 2 class IC drugs fl ecainide and propafenone, a beta-
blocker with class III activity sotalol, and a multiple class action drug 
amiodarone. The clinical niches and usage of these drugs are discussed 
elsewhere and will not be elaborated on here. The 6 so-called 
“strategy trials”, viz. PIAF,(12) STAF,(13) RACE,(14) AFFIRM,(15) HOT 
CAFÉ(16) and AF-CHF(17) concluded that rhythm control is not superior 
to rate control, so that it might well be questioned whether there is a 
point in new rhythm control drugs. It was however clear from a 
subsequent analysis of the largest of these trials, viz. AFFIRM that sinus 
rhythm was a very powerful predictor of survival (hazard ratio 0.54), 
but that this was offset by a powerful negative effect of the drugs used 
to control rhythm (hazard ratio 1.41).(18) Thus rhythm-controlling drugs 
without the adverse effects of the current generation are likely to have 
a survival benefi t. 
Future options for rhythm control are listed in Table III. Upstream 
therapy, also known as “primary prevention” refers to therapies which 
Major  Moderate Minor 
Previous thrombo-embolism Congestive heart failure Female gender
Mitral stenosis Hypertension Age 65-75 years
Prosthetic heart valve Age > 75 years Coronary artery disease
 Diabetes Echo: left atrial (LA) size
 Ejection fraction < 0.35 and LA appendage fl ow
  Thrombophilia
  Estrogen therapy
  Malignancy
TABLE 1:  Risk factors for thrombo-embolism in atrial fi brillation
Alternative to aspirin  Alternative to warfarin
Clopidogrel Anti-platelet
 Clopidogrel
 Indirect factor Xa inhibitors
 Idraparinux
 Biotinylated idraparinux







 Direct thrombin inhibitors
 Ximelagatran
 Dabigatran
TABLE 1l:  Future options for anti-coagulation in AF
modulate the electro-anatomical remodelling of substrate for atrial 
fi brillation. Benefi ts have been shown for prevention of atrial fi brillation 
by all 4 classes of blockers of the renin-angiotensin system, viz. 
ß-blockers, angiotensin converting enzyme(ACE)-inhibitors, angiotensin 
receptor blockers (ARBs) and aldosterone antagonists.  A recent meta-
analysis showed that ß-blockers in systolic heart failure resulted in a 
27% risk reduction for new-onset AF.(19) To what extent this is a direct 
anti-arrhythmic effect versus an indirect effect on blood pressure, pump 
function and prevention of myocardial infarction, is not clear. ACE-
inhibitors were fi rst shown in a small Dutch study with lisinopril to have 
a benefi t in the maintenance of sinus rhythm after cardioversion;(20) 
subsequently in a large post-MI trial with trandolopril there was a 
benefi t in AF prevention;(21) and in a large heart failure trial with enalapril 
(SOLVD) there was a similar benefi t.(22) In the case of ARBs, in a 
secondary prevention trial, Madrid from Madrid showed that irbesartan 
combined with amiodarone was better at maintenance of sinus rhythm 
after cardioversion than amiodarone alone.(23) Subsequently primary 
prevention of AF has been shown in large trials in hypertension with 
losartan (LIFE),(24) and in heart failure with valsartan (VAL-HeFT)(25) and 
candesartan (CHARM).(26) Recently a meta-analysis of prevention of AF 
with ACE-inhibitors and ARBs reported both to be effective provided 
that there was either LV hypertrophy or systolic dysfunction.(27) 
Statins have been mooted to have an anti-arrhythmic benefi t, 
particularly for atrial fi brillation, on the basis of experimental and 
observational clinical studies. This effect may be due to their anti-
infl ammatory or anti-oxidant properties, and they are known to have 
effects on matrix metallo-proteinases, nitric oxide synthesis and L-type 
calcium currents which may also translate into anti-arrhythmic benefi t. 
Earlier this year a meta-analysis of 6 studies and 3 557 patients showed 
a signifi cant benefi t, more marked in the 3 secondary prevention trials 
than in the 3 primary prevention trials (which were in patients having 
acute coronary syndrome or undergoing cardiac surgery).(28)
The background to anti-infl ammatory therapy is that 66% of atrial 
biopsies in lone AF have myocarditis, and C-reactive protein (CRP) 
levels are raised in AF, more so in permanent AF than in persistent 
AF and least so in paroxysmal AF. The success of cardioversion has 
been related to CRP levels and thrombo-embolic risk correlates 
with CRP levels. A study has shown that treatment with methyl-
prednisolone  successfully prevents recurrence and the development 
of permanence in atrial fi brillation, and that this also correlated with 
reduction in CRP levels.(29) 
Atrial fi brosis in structural heart disease is an important substrate 
for AF. Anti-fi brosis therapy includes the aldosterone antagonists 
spironolactone and eplerenone, and a specifi c anti-fi brotic drug 
pirfenidone. In a dog study, pirfenidone has been shown to signifi cantly 
reduce vulnerability to AF and atrial remodeling.(30) 
The superiority of amiodarone as an anti-fi brillatory drug has been 
attributed to its mode of action, which involves multiple channel 
blockade. Some newer drugs also have this property and include 
congeners of amiodarone and tedisamil (Figure 1). Tedisamil is a blocker 
of IKr, IKs, Ito, IKATP, INa, IKur  and in addition is a gap junction modulator (vide 
infra). The oral formulation has been abandoned because it causes 
diarrhea but the intravenous form is effective for chemical cardioversion 
of AF, with a half life of 8-13 hours so that early recurrence of atrial 
fi brillation is rare. The mean time to cardioversion is 35 minutes and 
the success rate is about 55% in AF but only about half that in atrial 
fl utter. The drug does prolong QT interval which resulted in ventricular 
tachycardia in 2 of 53 patients in the reported study.(31)    
Dronedarone, like amiodarone, blocks IKr, IKs, ICa-L, Ito, INa, IKach, alpha 
and beta adrenergic receptors, but contains no iodine and, as a 
result, has fewer side-effects especially thyroid and pulmonary. 
A number of clinical trials have been completed with this drug. DAFNE 
was a dose-ranging study comparing 400mg versus 600mg versus 
800mg BD and showed that 600mg and 800mg were no more effective, 
but caused more side-effects.(32) ANDROMEDA was a trial in heart 
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Omega-3 poly-unsaturated fatty acids
PPAR- modulators
Anti-oxidants
Multiple channel blockade   
Tedisamil
Amiodarone congeners – dronedarone
                                     celivarone
Atrial selectivity   
Atrial repolarization-delaying agents
ATI-2042 (amiodarone congener)
Serotonin 5HT4 receptor antagonists
TABLE 1ll:  Future options for rhythm control in AF
Other   
Gap junction / connexin modulators
Stretch - activated channel blockers
Na/Ca exchange inhibitors
New INa current blockers
IKach channel blockers
IKs channel blockers
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failure with an ejection fraction of <0.35, and was terminated 
prematurely in January 2003 because of an increased mortality of 8.1% 
with dronedarone compared to 3.8% on placebo, due to worsening 
heart failure. It is thought that a rise in serum creatinine from a renal 
tubular effect of the drug led to discontinuation of ACE-I/ARB therapy 
by clinicians.(33) EURIDIS and ADONIS were identical trials conducted 
in Europe and America showing the effi cacy of dronedarone at the 
maintenance of sinus rhythm after cardioversion with signifi cant success 
(hazard ratio = 0.75 and P<0.001) after 1 year follow-up.(34) The one-
year recurrence rate on dronedarone was 65%, whereas it was only 
25% with amiodarone in the Canadian trial of Atrial Fibrillation,(35) 
suggesting that it is not quite as effi cacious as amiodarone. In ATHENA, 
the biggest anti-arrhythmic drug trial to date with 4 628 patients, 
dronedarone was shown to signifi cantly reduce the primary endpoint, 
which was death or time to fi rst hospitalization for a cardiovascular 
reason, with a hazard ratio of 0.76 and a P<0.001. Most of the benefi t 
was in the reduction of hospitalization but cardiovascular deaths were 
also reduced signifi cantly. A rise in creatinine occurred in 4.7% of 
patients on dronedarone vs. 1% on placebo.(36) Celivarone is another 
amiodarone congener which is non-iodinated with a completed dose 
ranging trial (MAIA) and a completed trial on oral chemical cardioversion 
(CORYFREE) not reported yet. 
The attractive property of atrial selectivity is being pursued by a 
number of pharmaceutical investigators with a number of as yet 
unnamed molecules known as “atrial repolarization-delaying agents” 
such as  AVE 0118, S9947, S20951, ASD7009, NIP-141/2 and XEN-
D0101/2. The most advanced information concerns RSD1235 now 
called vernakalant, which blocks the IKur channel which is only found in 
the atria so that the drug has minimal effect on ventricular repolarization. 
It is also however a blocker of IKAch, Ito, and frequency and voltage 
dependent INa, so that this and the other drugs in this class are not 
completely atrial selective. It exhibits use dependency and has minimal 
hemodynamic effects. The intravenous form has been tested in a dose-
ranging phase 2 trial (CRAFT) as well as a series of phase 3 clinical trials 
(ACT I-IV), showing a 50% success rate in chemical cardioversion of 
short-duration AF in a median time of 11 minutes, but it is ineffective 
against atrial fl utter and only 27% effective in heart failure. No torsades 
de pointes has been seen. Sneezing, taste disturbance and nausea are 
side-effects.(37) An oral formulation for maintenance of sinus rhythm 
after cardioversion shows promise in phase 2 trials.(38) 
Serotonin infusion  is known to cause sinus tachycardia, atrial tachycardia 
and AF. Consequently antagonists of serotonin and specifi cally the 
5HT4  receptor, which is only found in the atria and not the ventricles, 
have been developed, viz. RS-1003002 and SB-207266 (now called 
FIGURE 1:  Ion currents determining the atrial action potential and the occurrence of each current in relation to the action potential, and agents which block each, are shown.
Arrows pointing to the left and downward rectangles (beige) indicate inward currents:  arrows pointing to the right and upward rectangles (blue) indicate outward currents.






















Inhibitors at therapeutic concentrations
NIP-151, NIP141/142, AVE0118, celivarone
Dronedarone
Vernakalant, tedisamil, dronedarone, celivarone, ATI-2042, 
pilsicainide, ranolazine (late lNa), AZD7009, NIP141/142
Vernakalant, tedisamil, dronedarone, AVE0118, AZD7009
JTV519, vernakalant, dronedarone, celivarone, ranolazine, 
NIP141/142
Vernakalant, XEN D0101, dronedarone, AVE0118, AVE1231, 
AZD7009, ATI-2042, NIP141/142
HMR1556 (selective), azimilide, dronedarone, celivarone, ATI-2042
Tedisamil, dronedarone, nifekalant, celivarone, ATI-2042, vernakalant, 
AZD7009
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piboserod). In a study piboserod has proved to be ineffective at 
maintaining sinus rhythm after cardioversion.  
The fi nal group of new drugs for rhythm control is a miscellaneous one, 
only sharing the fact that they have novel mechanisms of action. Gap 
junctions are physiologically important for rapid cell-to-cell conduction 
and are composed of connexons, which in turn are made up of 6 
connexins, numbers 40, 43 and 45 being found in the atrial myocardium. 
Some previously mentioned drugs, viz. losartan and tedisamil facilitate 
conduction through gap junctions, thereby increasing conduction 
velocity and shortening the effective refractory period. Interest is 
focused on specifi c gap junction modulators, and in particular GAP-
486 / ZP123, now called rotigaptide. This is a hexapeptide which 
augments gap junction conductance and improves cell-to-cell coupling. 
In dog experiments, rotigaptide reduces vulnerability to AF in a mitral 
regurgitation model but not in a heart failure model,(39) and in atrial 
ischemia, but not in an atrial tachycardia model.(40)   
Atrial dilatation may activate certain ion channels, and blockade 
of these channels by stretch activated channel blockers might be 
therapeutically useful. Substances known to have this property include 
gadolinium, amiloride, cationic antibiotics, and poly-unsaturated fatty 
acids. A selective blocker of these channels exists in the venom of the 
Chilean Rose tarantula spider, a 35-amino acid peptide known as 
GsMTx-4.
The Na-Ca exchange mechanism on myocyte membranes normally 
moves 3 molecules of Na into the cell for every one molecule of Ca 
moving out of the cell. In rapid atrial pacing or fi brillation, this exchange 
is reversed. Inhibitors of  Na-Ca exchange prevent this reversal. An 
example is KB-R7943 which blocks a number of other channels also.     
Ranolazine is a piperazine derivative with anti-anginal / anti-ischemic 
properties and was investigated in the MERLIN-TIMI 36 trial where it 
was shown to signifi cantly reduce unsustained ventricular tachycardia 
and supra-ventricular tachycardia incidence, and it also reduced the 
incidence of new AF, albeit not signifi cantly (1.7% vs. 2.4%, P=0.08).(41) 
Ranolazine uniquely is an inhibitor of the late phase of the inward 
sodium current (late INa) but is also a blocker of multiple other channels 
including peak INa, IKr, IKs, ICaL and Na-Ca exchange. It causes minimal QTc 
prolongation (2-6mS).     
CONCLUSION
Although a strategy of ventricular rate control may not be inferior to 
rhythm control in some patients with AF, drug treatment for rhythm 
control is likely to increase in the future as a result both of the increasing 
incidence of atrial fi brillation as well as the development of exciting 
new drugs which will not have adverse effects, especially pro-arrhythmia. 
Advances in ablation techniques for AF will have an impact only on a 
small segment of the patient population. Hopefully new anti-coagulants 
will be unburdened from the need for frequent laboratory testing in 
the future.    
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